| Bioactivity | IRAK4-IN-4 is an interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor extracted from patent CN107163044A, Compound15, has an IC50 of 2.8 nM. IRAK4-IN-4 also inhibits cyclic GMP-AMP synthase (cGAS) with an IC50 of 2.1 nM[1]. | ||||||||||||
| Target | IC50: 2.8 nM (IRAK4), 2.1 nM (cGAS) | ||||||||||||
| Name | IRAK4-IN-4 | ||||||||||||
| CAS | 1850276-58-2 | ||||||||||||
| Formula | C22H16N2O2 | ||||||||||||
| Molar Mass | 340.37 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. One class has the naphthalene second dione compounds and its derivative of protease modification activities. CN107163044A. |
IRAK4-IN-4
CAS: 1850276-58-2 F: C22H16N2O2 W: 340.37
IRAK4-IN-4 is an interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor extracted from patent CN107163044A, Compou
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.